Walter R, Gale R
Leukemia. 2024; 38(8):1647-1648.
PMID: 38937547
DOI: 10.1038/s41375-024-02295-7.
Blachly J, Walter R, Hourigan C
Haematologica. 2022; 107(12):2810-2822.
PMID: 36453518
PMC: 9713561.
DOI: 10.3324/haematol.2022.282034.
Gale R
Blood Sci. 2022; 4(4):209-210.
PMID: 36311818
PMC: 9595042.
DOI: 10.1097/BS9.0000000000000112.
Roug A, Ommen H
Curr Treat Options Oncol. 2019; 20(4):28.
PMID: 30874904
DOI: 10.1007/s11864-019-0627-4.
Ravandi F, Walter R, Freeman S
Blood Adv. 2018; 2(11):1356-1366.
PMID: 29895626
PMC: 5998930.
DOI: 10.1182/bloodadvances.2018016378.
Measurable residual disease testing in acute myeloid leukaemia.
Hourigan C, Gale R, Gormley N, Ossenkoppele G, Walter R
Leukemia. 2017; 31(7):1482-1490.
PMID: 28386105
DOI: 10.1038/leu.2017.113.
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mule M, Mannis G, Wood B, Radich J, Hwang J, Ramos N
Biol Blood Marrow Transplant. 2016; 22(11):1974-1982.
PMID: 27544285
PMC: 5072749.
DOI: 10.1016/j.bbmt.2016.08.014.
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K, Stock W, Walter R
Leuk Lymphoma. 2016; 57(7):1527-33.
PMID: 27269126
PMC: 4968046.
DOI: 10.3109/10428194.2016.1160085.
Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y, Othus M, Araki D, Wood B, Radich J, Halpern A
Leukemia. 2016; 30(7):1456-64.
PMID: 27012865
PMC: 4935622.
DOI: 10.1038/leu.2016.46.
New drug approvals in acute myeloid leukemia: what's the best end point?.
Estey E, Othus M, Lee S, Appelbaum F, Gale R
Leukemia. 2015; 30(3):521-5.
PMID: 26677969
PMC: 4777773.
DOI: 10.1038/leu.2015.262.
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.
Hokland P, Ommen H, Mule M, Hourigan C
Semin Hematol. 2015; 52(3):184-92.
PMID: 26111465
PMC: 4484880.
DOI: 10.1053/j.seminhematol.2015.04.001.
Who is the best alternative allotransplant donor?.
Gale R, Eapen M
Bone Marrow Transplant. 2015; 50 Suppl 2:S40-2.
PMID: 26039206
PMC: 4520408.
DOI: 10.1038/bmt.2015.94.
A multigene array for measurable residual disease detection in AML patients undergoing SCT.
Goswami M, McGowan K, Lu K, Jain N, Candia J, Hensel N
Bone Marrow Transplant. 2015; 50(5):642-51.
PMID: 25665046
PMC: 4424111.
DOI: 10.1038/bmt.2014.326.
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
Cross N, White H, Colomer D, Ehrencrona H, Foroni L, Gottardi E
Leukemia. 2015; 29(5):999-1003.
PMID: 25652737
PMC: 4430701.
DOI: 10.1038/leu.2015.29.
Next generation MRD.
Hourigan C
Biol Blood Marrow Transplant. 2014; 20(9):1259-60.
PMID: 25016196
PMC: 4209896.
DOI: 10.1016/j.bbmt.2014.07.002.
Should persons with acute myeloid leukemia have a transplant in first remission?.
Gale R, Wiernik P, Lazarus H
Leukemia. 2014; 28(10):1949-52.
PMID: 24727674
DOI: 10.1038/leu.2014.129.
